grant
Mechanism of alpha5 integrin contribution to Amyotrophic Lateral Sclerosis pathology.
Organization OREGON HEALTH & SCIENCE UNIVERSITYLocation PORTLAND, UNITED STATESPosted 1 Apr 2026Deadline 31 Mar 2031
NIHUS FederalResearch GrantFY2026AD dementiaALS pathologyALS patientsAccelerationAffectAlzheimer Type DementiaAlzheimer disease dementiaAlzheimer sclerosisAlzheimer syndromeAlzheimer'sAlzheimer's DiseaseAlzheimers DementiaAmyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis Motor Neuron DiseaseAmyotrophic Lateral Sclerosis patientsAutomobile DrivingBody TissuesCD11bCD49e AntigensCR3ACRISPR approachCRISPR based approachCRISPR methodCRISPR methodologyCRISPR techniqueCRISPR technologyCRISPR toolsCRISPR-CAS-9CRISPR-based methodCRISPR-based techniqueCRISPR-based technologyCRISPR-based toolCRISPR/CAS approachCRISPR/Cas methodCRISPR/Cas technologyCRISPR/Cas9CRISPR/Cas9 technologyCas nuclease technologyCell BodyCell FunctionCell LocomotionCell MigrationCell MovementCell PhysiologyCell ProcessCell TransplantationCell modelCell-Extracellular MatrixCellsCellular FunctionCellular MigrationCellular MotilityCellular PhysiologyCellular ProcessCellular modelCessation of lifeChemotaxisClustered Regularly Interspaced Short Palindromic Repeats approachClustered Regularly Interspaced Short Palindromic Repeats methodClustered Regularly Interspaced Short Palindromic Repeats methodologyClustered Regularly Interspaced Short Palindromic Repeats techniqueClustered Regularly Interspaced Short Palindromic Repeats technologyCold-Insoluble GlobulinsDataDeathDegenerative Neurologic DisordersDevelopmentDiagnosisDiseaseDisease ProgressionDisease associated microgliaDisorderECMEnzyme GeneEnzymesExtracellular MatrixFN1FNRAFibronectin 1Fibronectin Receptor Alpha SubunitFibronectinsGehrig's DiseaseGene TranscriptionGeneticGenetic ModelsGenetic TranscriptionGliaGlial CellsHortega cellITGA5ITGA5 geneITGAMITGAM geneImmuneImmune Modulation TherapyImmunesInfiltrationInflammationInflammatoryIntegrin Alpha 5Integrin alpha5Integrin alphaFIntegrin α5InterventionInvestigationKO miceKnock-out MiceKnockout MiceKnowledgeKolliker's reticulumLETS ProteinsLarge External Transformation-Sensitive ProteinLigandsLinkLou Gehrig DiseaseMAC1AMO1AMacrophageMiceMice MammalsMicrogliaModelingMolecularMotor CellMotor NeuronsMurineMusMyelogenousMyeloidMyeloid Cell ActivationMyeloid CellsMφNerve CellsNerve DegenerationNerve UnitNervous System Degenerative DiseasesNeural CellNeural Degenerative DiseasesNeural degenerative DisordersNeurocyteNeurodegenerative DiseasesNeurodegenerative DisordersNeurogliaNeuroglial CellsNeurologic Degenerative ConditionsNeuron DegenerationNeuronsNon-neuronal cellNonneuronal cellNull MouseOnset of illnessOpsonic GlycoproteinOpsonic alpha(2)SB GlycoproteinPathogenesisPathologicPathway interactionsPeripheralPeripheral NervesPersonsPhagocytosisPlatelet Glycoprotein IcPopulationPrimary Senile Degenerative DementiaProteinsQOL improvementRNA ExpressionRoleSOD-1SOD-1 proteinSOD1SOD1 geneSOD1 gene productSeminalStressSubcellular ProcessSystemTestingTissuesTranscriptionTranslationsUnited StatesVLA-5 alpha ChainVLA5AWorkalpha 2-Surface Binding Glycoproteinalpha(5) Integrinamyotrophic lateral sclerosis pathologycell behaviorcell motilitycell typecellular behaviorcellular transplantclinical applicabilityclinical applicationconditional knock-outconditional knockoutdegenerative diseases of motor and sensory neuronsdegenerative neurological diseasesdevelopmentaldisease onsetdisease subgroupsdisease subtypedisorder onsetdisorder subtypedrivingfALSfamilial ALSfamilial amyotrophic lateral sclerosisgenome editinggenomic editinggitter cellhiPSChuman iPShuman iPSChuman induced pluripotent cellhuman induced pluripotent stem cellshuman inducible pluripotent stem cellshuman inducible stem cellsiPSiPSCiPSCsimmune modulatory therapiesimmune modulatory treatmentimmune regulation therapyimmune regulation treatmentimmune regulatory therapyimmune-modulation treatmentimmunomodulation therapyimmunomodulation treatmentimmunomodulator therapiesimmunomodulator treatmentimmunomodulator-based therapiesimmunomodulatory biologicsimmunomodulatory therapiesimmunomodulatory treatmentimmunoregulatory therapyimmunoregulatory treatmentimprovements in QOLimprovements in quality of lifeinduced human pluripotent stem cellsinduced pluripotent cellinduced pluripotent stem cellinducible pluripotent cellinducible pluripotent stem cellinsightmesogliamicroglial cellmicrogliocytemigrationmotoneuronmotor neuron degenerationmouse modelmurine modelmutantnerve cell deathnerve cell lossnerve cementneural degenerationneurodegenerationneurodegenerativeneurodegenerative illnessneurological degenerationneuron cell deathneuron cell lossneuron deathneuron lossneuron toxicityneuronalneuronal cell deathneuronal cell lossneuronal deathneuronal degenerationneuronal lossneuronal toxicityneuroprotectionneuroprotectiveneurotoxicneurotoxicitynew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynovelnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachpathology in ALSpathwayperivascular glial cellpreservationprimary degenerative dementiaprogramsquality of life improvementsALSscRNA sequencingscRNA-seqscreeningscreeningssenile dementia of the Alzheimer typesingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell technologysingle cell transcriptomic profilingsingle-cell RNA sequencingsocial rolespatial RNA sequencingspatial gene expression analysisspatial gene expression profilingspatial resolved transcriptome sequencingspatial transcriptome analysisspatial transcriptome profilingspatial transcriptome sequencingspatial transcriptomicsspatially resolved transcriptomicsspatio transcriptomicssporadic ALSsporadic amyotrophic lateral sclerosissuperoxide dismutase 1synaptic pruningtherapeutic immunomodulationtherapeutic immunoregulationtranslation
Description preview
Project Summary/Abstract
Amyotrophic Lateral Sclerosis (ALS) is the third most common neurodegenerative disease, with no cure and
limited treatment options. While motor neurons are primarily affected, non-neuronal cells, particularly myeloid
cells (microglia and peripheral macrophages), significantly influence disease progression. Our preliminary…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click